[
  {
    "text": "CO-PROMOTION AGREEMENT",
    "bbox": [
      500,
      141,
      832,
      153
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
    "bbox": [
      179,
      175,
      1000,
      190
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
    "bbox": [
      113,
      196,
      1000,
      208
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
    "bbox": [
      112,
      214,
      1000,
      228
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "and together as the \"Parties\"",
    "bbox": [
      113,
      232,
      365,
      247
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "RECITALS",
    "bbox": [
      611,
      268,
      721,
      280
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
    "bbox": [
      179,
      301,
      1000,
      318
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
    "bbox": [
      181,
      338,
      1000,
      351
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
    "bbox": [
      113,
      357,
      1000,
      371
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "activities, for the Product in the Territory;",
    "bbox": [
      112,
      375,
      458,
      390
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
    "bbox": [
      179,
      411,
      1000,
      425
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
    "bbox": [
      114,
      431,
      1000,
      443
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
    "bbox": [
      415,
      521,
      918,
      530
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 17,
    "category": "Change Of Control"
  },
  {
    "text": "CO-PROMOTION AGREEMENT",
    "bbox": [
      500,
      141,
      832,
      153
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
    "bbox": [
      179,
      175,
      1000,
      190
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
    "bbox": [
      113,
      196,
      1000,
      208
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
    "bbox": [
      112,
      214,
      1000,
      228
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "and together as the \"Parties\"",
    "bbox": [
      113,
      232,
      365,
      247
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "RECITALS",
    "bbox": [
      611,
      268,
      721,
      280
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
    "bbox": [
      179,
      301,
      1000,
      318
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
    "bbox": [
      181,
      338,
      1000,
      351
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
    "bbox": [
      113,
      357,
      1000,
      371
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "activities, for the Product in the Territory;",
    "bbox": [
      112,
      375,
      458,
      390
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
    "bbox": [
      179,
      411,
      1000,
      425
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
    "bbox": [
      114,
      431,
      1000,
      443
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
    "bbox": [
      415,
      521,
      918,
      530
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 21,
    "category": "Minimum Commitment"
  },
  {
    "text": "CO-PROMOTION AGREEMENT",
    "bbox": [
      500,
      141,
      832,
      153
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "This Co-Promotion Agreement (this \"Agreement\"') is entered into and dated as of September 26, 2018 (the \"Effective",
    "bbox": [
      179,
      175,
      1000,
      190
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "Date'') by and between Dova Pharmaceuticals, Inc., a Delaware corporation (\"Dova''), and Valeant Pharmaceuticals North.",
    "bbox": [
      113,
      196,
      1000,
      208
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "America LLC, a Delaware limited liability company (\"Valeant'). Dova and Valeant are each referred to individually as a \"Party'",
    "bbox": [
      112,
      214,
      1000,
      228
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "and together as the \"Parties\"",
    "bbox": [
      113,
      232,
      365,
      247
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "RECITALS",
    "bbox": [
      611,
      268,
      721,
      280
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "WHEREAS, Dova has developed and has rights to market and sell the Product (as defined below) in the Territory;",
    "bbox": [
      179,
      301,
      1000,
      318
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "WHEREAS, the Parties believe that it would be mutually beneficial to collaborate on promotional activities for the.",
    "bbox": [
      181,
      338,
      1000,
      351
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "Product and, accordingly, Dova desires that Valeant conduct certain promotional activities, and Valeant desires to conduct such",
    "bbox": [
      113,
      357,
      1000,
      371
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "activities, for the Product in the Territory;",
    "bbox": [
      112,
      375,
      458,
      390
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "NOW, THEREFORE, in consideration of the following mutual promises and obligations, and for other good and valuable",
    "bbox": [
      179,
      411,
      1000,
      425
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "consideration the adequacy and sufficiency of which are hereby acknowledged, the Parties agree as follows:",
    "bbox": [
      114,
      431,
      1000,
      443
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION",
    "bbox": [
      415,
      521,
      918,
      530
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  },
  {
    "text": "Source: DOVA PHARMACEUTICALS INC., 10-Q, 11/8/2018",
    "bbox": [
      133,
      1000,
      593,
      1000
    ],
    "label": 39,
    "category": "Covenant Not To Sue"
  }
]